2020 American Transplant Congress
Three Year Post Co-Stimulation Blocking Agent (Belatacept) Switch Outcomes of Kidney Transplant Patients Diagnosed with Post-Transplant Thrombotic Microangiopathy
*Purpose: Thrombotic microangiopathy (TMA) can happen after kidney transplant. It may occur de novo or as a recurrent disease. De novo is usually associated with…2020 American Transplant Congress
Belatacept Conversion: Are Patients BENEFIT-ing
Columbia University Irving Medical Center, New York, NY
*Purpose: Belatacept is increasingly used in renal transplant recipients experiencing adverse effects from calcineurin inhibitors(CNI) despite limited medium- and long- term data on safety and…2020 American Transplant Congress
Clinicopathological Evaluation of Long-Term Survivor More Than 10 Years after Living Kidney Transplant with Corticosteroid Early Withdrawal Protocol
*Purpose: We have previously reported that favorable short-term outcomes of kidney recipients were achieved by corticosteroid early withdrawal protocol (CSEW) compared to the conventional protocol…2020 American Transplant Congress
Metformin Improves Biomarkers of Calcineurin Inhibitor Related Nephrotoxicity
Department of Nephrology, Prince of Wales Hospital, Randwick, Australia
*Purpose: Calcineurin Inhibitors (CNIs) prevent transplant rejection but cause significant nephrotoxicity. Biomarkers of CNI nephrotoxicity could help drug dosing and improve long-term graft outcomes. As…2020 American Transplant Congress
Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Treatment of Patients with Hepatitis B Following Liver Transplantation
*Purpose: Taiwan has a high prevalence of hepatitis B (HBV) and HBV related end-stages liver diseases are the leading causes of liver transplantation (LT). Tenofovir…2020 American Transplant Congress
Protective Effect of Fucoidan Against Tacrolimus-Induced Nephrotoxicity in LLC-PK1 Cells
Surgery, University of Ulsan, Gangneung Asan Hospital, Gangneung, Korea, Republic of
*Purpose: Tacrolimus (FK506) is an immunosuppressant agent that is frequently used to prevent rejection of solid organs upon transplant. However, nephrotoxicity due to apoptosis and…2019 American Transplant Congress
Discovery and Validation of an Early Post-Transplant Biomarker Model Predictive of Chronic Kidney Disease in Liver Transplant Recipients
*Purpose: A significant proportion of patients develop chronic kidney disease after liver transplantation (LT). We aimed to develop clinical/protein models to predict future GFR deterioration…2019 American Transplant Congress
Renal Failure as a Complication of Vascularized Composite Allotransplantation
*Purpose: Vascularized composite allotransplantation (VCA) has demonstrated impressive outcomes in areas of extremity (UETx), face (FTx), genitourinary, and abdominal wall transplantation with up to twenty…2019 American Transplant Congress
Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population
University of Illinois at Chicago, Chicago, IL
*Purpose: Conversion to belatacept as maintenance immunosuppression has gained traction to prevent calcineurin inhibitor (CNI) induced toxicities in renal transplant (RTx) recipients. However, limited knowledge…2019 American Transplant Congress
Abatacept as Rescue Immunosuppression after Calcineurin Inhibitor Treatment Failure in Renal Transplantation
Emory University School of Medicine, Atlanta, GA
*Purpose: A majority of kidney transplant recipients receive calcineurin inhibitor (CNI)-based immunosuppression. However, some do not tolerate CNIs and require other immunosuppressive strategies. Until recently,…
American Transplant Congress abstracts